Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Sep 2025 is 18.34% vs 7.64% in Sep 2024
Consolidate Net Profit
YoY Growth in quarter ended Sep 2025 is 128.35% vs -42.70% in Sep 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Sep 2025 is 35.06% vs -4.05% in Sep 2024
Interest
YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Sep 2025 has improved from Sep 2024
Compare Quarterly Results Of Theravance Biopharma, Inc. With
Quarterly - Net Sales
QoQ Growth in quarter ended Sep 2025 is -23.66% vs 70.13% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 18.34% vs 7.64% in Sep 2024
Quarterly - Consolidate Net Profit
QoQ Growth in quarter ended Sep 2025 is -93.43% vs 502.94% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 128.35% vs -42.70% in Sep 2024
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Sep 2025 is -257.14% vs 90.91% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 35.06% vs -4.05% in Sep 2024
Quarterly - Interest
QoQ Growth in quarter ended Sep 2025 is -14.29% vs 16.67% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025
YoY Growth in quarter ended Sep 2025 has improved from Sep 2024






